These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 16682690)

  • 1. Sildenafil increases cerebrovascular reactivity: a transcranial Doppler study.
    Brenner S
    Neurology; 2006 May; 66(9):1455-6; author reply 1455-6. PubMed ID: 16682690
    [No Abstract]   [Full Text] [Related]  

  • 2. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects.
    Kruuse C; Thomsen LL; Jacobsen TB; Olesen J
    J Cereb Blood Flow Metab; 2002 Sep; 22(9):1124-31. PubMed ID: 12218418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of erectile dysfunction. Hard facts support sildenafil].
    MMW Fortschr Med; 2003 Sep; 145(35-36):50-1. PubMed ID: 14584211
    [No Abstract]   [Full Text] [Related]  

  • 4. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.
    Reffelmann T; Kloner RA
    Circulation; 2003 Jul; 108(2):239-44. PubMed ID: 12860892
    [No Abstract]   [Full Text] [Related]  

  • 5. Systemic administration of phosphodiesterase V inhibitor, sildenafil citrate, for attenuation of cerebral vasospasm after experimental subarachnoid hemorrhage.
    Atalay B; Caner H; Cekinmez M; Ozen O; Celasun B; Altinors N
    Neurosurgery; 2006 Nov; 59(5):1102-7; discussion 1107-8. PubMed ID: 17143244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic nucleotide phosphodiesterase 5 and sildenafil: promises realized.
    Manganiello V
    Mol Pharmacol; 2003 Jun; 63(6):1209-11. PubMed ID: 12761329
    [No Abstract]   [Full Text] [Related]  

  • 7. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?
    Burnett AL
    Urology; 2005 Feb; 65(2):224-30. PubMed ID: 15708027
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb.
    Jaillard S; Larrue B; Deruelle P; Delelis A; Rakza T; Butrous G; Storme L
    Ann Thorac Surg; 2006 Mar; 81(3):935-42. PubMed ID: 16488698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type V phosphodiesterase expression in cerebral arteries with vasospasm after subarachnoid hemorrhage in a canine model.
    Inoha S; Inamura T; Ikezaki K; Nakamizo A; Amano T; Fukui M
    Neurol Res; 2002 Sep; 24(6):607-12. PubMed ID: 12238630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sildenafil: emerging cardiovascular indications.
    Raja SG; Nayak SH
    Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [In sex dysfunctions--not just a "male issue". Don't forget women].
    MMW Fortschr Med; 2003 Sep; 145(35-36):51. PubMed ID: 14584212
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of Sildenafil on human platelet secretory function is controlled by a complex interplay between phosphodiesterases 2, 3 and 5.
    Dunkern TR; Hatzelmann A
    Cell Signal; 2005 Mar; 17(3):331-9. PubMed ID: 15567064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relaxation effect of nitric oxide-donor on diabetic penile smooth muscle in vitro.
    Taher A; Birowo P; Kamil ST; Shahab N
    Clin Hemorheol Microcirc; 2000; 23(2-4):277-81. PubMed ID: 11321451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension.
    Weimann J; Ullrich R; Hromi J; Fujino Y; Clark MW; Bloch KD; Zapol WM
    Anesthesiology; 2000 Jun; 92(6):1702-12. PubMed ID: 10839922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED.
    Boyle CD; Xu R; Asberom T; Chackalamannil S; Clader JW; Greenlee WJ; Guzik H; Hu Y; Hu Z; Lankin CM; Pissarnitski DA; Stamford AW; Wang Y; Skell J; Kurowski S; Vemulapalli S; Palamanda J; Chintala M; Wu P; Myers J; Wang P
    Bioorg Med Chem Lett; 2005 May; 15(9):2365-9. PubMed ID: 15837326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
    Carson CC
    J Urol; 2002 Jul; 168(1):205. PubMed ID: 12073960
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological preconditioning with sildenafil: Basic mechanisms and clinical implications.
    Kukreja RC; Salloum F; Das A; Ockaili R; Yin C; Bremer YA; Fisher PW; Wittkamp M; Hawkins J; Chou E; Kukreja AK; Wang X; Marwaha VR; Xi L
    Vascul Pharmacol; 2005; 42(5-6):219-32. PubMed ID: 15922255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type 5 phosphodiesterase inhibition: the focus shifts to the heart.
    Semigran MJ
    Circulation; 2005 Oct; 112(17):2589-91. PubMed ID: 16246958
    [No Abstract]   [Full Text] [Related]  

  • 19. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
    Steiner MK; Preston IR; Klinger JR; Hill NS
    Curr Opin Pharmacol; 2005 Jun; 5(3):245-50. PubMed ID: 15907910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxation and cyclic GMP levels in response to sildenafil in human pulmonary arteries from donors.
    Mauricio MD; Segarra G; Medina P; Aldasoro M; Martínez-León JB; Vila JM
    Eur J Pharmacol; 2006 Jan; 530(3):259-62. PubMed ID: 16380114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.